
    
      This is a randomized, double-blind, placebo-controlled, parallel-group, single-center study
      (Figure 1). Thirty subjects will be randomized in a 3:2 randomization ratio to canagliflozin
      300 mg once daily (QD) or placebo. The study will include a 3-week pretreatment screening
      phase and a 4-week double-blind treatment phase.
    
  